Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hansoh Adds Global Rights for Zhuhai’s Bispecific in $700 Million Deal

publication date: Mar 15, 2024

Jiangsu Hansoh Pharma extended its partnership with Zhuhai Biotheus, acquiring global rights to Zuhai’s proprietary anti-EGFR/cMet bispecific antibody in a $700 million agreement. Two years ago, Hansoh acquired China rights to the candidate for $207 million. Now, the company will be in charge of taking the bispecific to global markets, although it does also have rights to sublicense it. Zhuhai’s candidate is a 1+1 heterodimeric EGFR/cMet bispecific antibody, designed to inhibit the growth and survival of tumors. It is currently in Phase I clinical trials to treat solid tumors including non-small-cell lung cancer. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital